Business Models & Investment Subcommittee

Charter

The Business Models & Investment Subcommittee strives to:

  • Map out the manufacturing process and considerations as they relate to optimizing the Business Model, including reimbursement and adoption into standard of care, for both autologous and allogeneic cell therapy products.

Projects and Objectives

  • The  Business Models & Investment Subcommittee will collect information from ISCT stakeholders via online surveys to assist in the development of educational webinars, white papers and roadmaps to support decision-making in cell therapy manufacturing.

 


 

Committee Chair


 

Bill Milligan
Co-Chair
Steminent Biotherapeutics Inc.
Vancouver, BC, Canada 

Patrick Rivers, MBA
Co-Chair

Aquilo Capital
San Francisco, CA, United States

 

Committee Members

 

Matthew Durdy, MBA
Cell and Gene Therapy Catapult
London, England

Suzanne Farid, PhD
University College London
London, England

Brian Hawkins, PhD
BioLife Solutions
Bothwell, WA, United States

Brad King, MBA
Cook Regentec
Indianapolis, IN, United States

Duncan Liew, PhD
Irvine Scientific
San Diego, CA, United States

Sarah Martin
Terumo BCT
Denver, CO, United States
Michael May
CCRM
Toronto, ON, Canada

Jennifer Moody, PhD
Blue Rock Therapeutics
Toronto, ON, Canada

Charles Mooney
Oklahoma Blood Institute
Oklahoma City, OK, United States

Benjamin Nelson, MBA
Fresenius Kabi
Lake Zurich, IL, United States

Colin Lee Novick
CJ Partners Inc
Tokyo, Japan

Olaf Zoellner, PhD
BD BioSciences
San Jose, CA, United States

Allen Chen, PhD
ASTAR
Singapore

© 2018 ISCT. All rights reserved. 
ISCT, and the ISCT logo are registered service marks of the International Society for Cellular Therapy.
The BEACON and lighthouse logo is a service mark of the International Society for Cellular Therapy.